We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-3.23%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.84B
AUM Growth
-$282M
Cap. Flow
-$43.3M
Cap. Flow %
-0.89%
Top 10 Hldgs %
88.92%
Holding
82
New
22
Increased
15
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$19.3M
2
TSLA icon
Tesla
TSLA
+$17M
3
USFD icon
US Foods
USFD
+$12.2M
4
FOLD
Amicus Therapeutics
FOLD
+$8.74M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.93M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$37.2M
2
MA icon
Mastercard
MA
+$18.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.2M
4
JPM icon
JPMorgan Chase
JPM
+$12.5M
5
DAL icon
Delta Air Lines
DAL
+$9.74M

Sector Composition

Rank Sector Weight
1 Consumer Staples 55.65%
2 Healthcare 23%
3 Consumer Discretionary 8.41%
4 Financials 1.55%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.68B 55.4%
114,987,547
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$825M 17.04%
57,517,977
– –
WW
3
DELISTED
WW International
WW
$342M 7.07%
29,443,300
– –
GS icon
4
CALL
Goldman Sachs
GS
$289B
$186M 3.83%
1,250,000
+250,000
+25% +$39M
BAC icon
5
CALL
Bank of America
BAC
$429B
$66.3M 1.37%
5,000,000
+500,000
+11% +$7.02M
INCY icon
6
Incyte
INCY
$25.4B
$50M 1.03%
625,000
+25,000
+4% +$1.94M
REGN icon
7
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$41.9M 0.87%
120,000
+90,000
+300% +$34.7M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$38.3B
$39.4M 0.81%
710,000
+110,000
+18% +$6.93M
WMT icon
9
CALL
Walmart Inc
WMT
$909B
$36.5M 0.75%
1,500,000
– –
BIIB icon
10
CALL
Biogen
BIIB
$30.9B
$36.3M 0.75%
150,000
-250,000
-63% -$65.9M
BABA icon
11
Alibaba
BABA
$276B
$31.8M 0.66%
400,000
+25,000
+7% +$1.96M
GS icon
12
Goldman Sachs
GS
$289B
$29.7M 0.61%
200,000
– –
GOOGL icon
13
CALL
Alphabet (Google) Class A
GOOGL
$4.12T
$28.1M 0.58%
+800,000
New +$29.4M
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.9B
$27.2M 0.56%
350,000
-50,000
-13% -$4.25M
NKTR icon
15
Nektar Therapeutics
NKTR
$2.39B
$19.9M 0.41%
93,333
-40,000
-30% -$8.94M
MET icon
16
CALL
MetLife
MET
$62.4B
$19.9M 0.41%
561,000
-280,500
-33% -$10.9M
CELG
17
CALL
DELISTED
Celgene Corp
CELG
$19.7M 0.41%
200,000
-100,000
-33% -$10.3M
BLUE
18
DELISTED
bluebird bio
BLUE
$19.5M 0.4%
34,740
-3,860
-10% -$2.19M
REGN icon
19
Regeneron Pharmaceuticals
REGN
$72.9B
$17.5M 0.36%
+50,000
New +$19.3M
APTV icon
20
Aptiv
APTV
$12.3B
$17.2M 0.36%
275,000
– –
ALNY icon
21
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$16.6M 0.34%
300,000
+150,000
+100% +$9.45M
KITE
22
DELISTED
Kite Pharma, Inc.
KITE
$16.3M 0.34%
325,000
-160,000
-33% -$7.86M
TSLA icon
23
Tesla
TSLA
$1.18T
$15.9M 0.33%
+1,125,000
New +$17M
AGIO icon
24
Agios Pharmaceuticals
AGIO
$2.08B
$15.7M 0.32%
375,000
+40,000
+12% +$1.98M
JPM icon
25
CALL
JPMorgan Chase
JPM
$916B
$15.5M 0.32%
250,000
– –
1
2 3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2016 Portfolio in Review

As of Q2 2016, Artal Group held 82 positions worth $4.84B, down 5.5% from $5.13B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group's Q2 2016 filing shows 22 new, 15 increased, 12 reduced and 13 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M. The largest sale was Celgene Corp, an estimated $37.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 56% of assets, down from 58% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Artal Group's largest Q2 2016 buy was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q2 2016, an estimated $6.93M increase.
  • Artal Group's biggest Q2 2016 reduction was Nektar Therapeutics, cutting an estimated $8.94M.
  • Artal Group fully exited Celgene Corp in Q2 2016, selling an estimated $37.2M.
  • Artal Group's ten largest holdings make up 89% of its $4.84B portfolio in Q2 2016.
  • Artal Group opened 22 new positions and closed 13 in Q2 2016.
  • Artal Group's portfolio value fell 5.5% quarter-over-quarter to $4.84B.

Based on Artal Group's 13F filing for Q2 2016, filed 11 Aug 2016.